Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000825166 | SCV000966438 | likely benign | not specified | 2017-08-23 | criteria provided, single submitter | clinical testing | p.Asp296Asn in exon 8 of ESRRB: This variant is not expected to have clinical si gnificance because it has been identified in 0.60% (21/3518) of Latino chromosom es by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; db SNP rs145982062). |
Gene |
RCV001577741 | SCV001805173 | likely benign | not provided | 2021-04-13 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001577741 | SCV005217760 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Ambry Genetics | RCV000825166 | SCV005997056 | uncertain significance | not specified | 2025-02-28 | criteria provided, single submitter | clinical testing | The c.886G>A (p.D296N) alteration is located in exon 8 (coding exon 5) of the ESRRB gene. This alteration results from a G to A substitution at nucleotide position 886, causing the aspartic acid (D) at amino acid position 296 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003975336 | SCV004795553 | likely benign | ESRRB-related disorder | 2022-10-14 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |